Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Biomol Ther (Seoul) ; 28(1): 104-109, 2020 Jan 01.
Article in English | MEDLINE | ID: mdl-31474032

ABSTRACT

Probenecid is a representative drug used in the treatment of gout. A recent study showed that probenecid effectively inhibits oxidative stress in neural cells. In the present study, we investigated whether probenecid can affect osteoclast formation through the inhibition of reactive oxygen species (ROS) formation in RAW264.7 cells. Lipopolysaccharide (LPS)-induced ROS levels were dose-dependently reduced by probenecid. Fluorescence microscopy analysis clearly showed that probenecid inhibits the generation of ROS. Western blot analysis indicated that probenecid affects two downstream signaling molecules of ROS, cyclooxygenase 2 (COX-2) and c-Jun N-terminal kinase (JNK). These results indicate that probenecid inhibits ROS generation and exerts antiosteoclastogenic activity by inhibiting the COX-2 and JNK pathways. These results suggest that probenecid could potentially be used as a therapeutic agent to prevent bone resorption.

2.
J Recept Signal Transduct Res ; 37(6): 550-559, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28853308

ABSTRACT

Parkinson's disease (PD) is the second most common neurodegenerative disease in the elderly. In central nervous system, astrocytes regulates neuronal function via the modulation of synaptic transmission and plasticity, secretion of growth factors, uptake of neurotransmitters and regulation of extracellular ion concentrations and metabolic support of neurons. Therefore, C6 astroglial cells have been used to study the in vitro PD model induced by 1-methyl-4-phenyl pyridinium (MPP+). In this study, pre-treatment of insulin inhibited MPP+-induced cell membrane damages on LDH and NO releases, which also inhibited the iNOS and Cox-2 levels. Insulin also up-regulated the PI3K and p-GSK-3ß protein expressions in C6 cells. In addition, MPP+ and/or insulin enhanced the autophagy by increasing LC3-I to LC3-II conversion. Furthermore, MPP+-induced toxicity diminished the integrin ß3, αV, syndecan-1 and -3. Insulin pre-treatment enhanced the phosphorylation of integrin-linked kinase and further induced the integrin and syndecan molecules. These findings suggest that insulin prevents MPP+-induced toxicity through activation of PI3K, p-GSK-3ß, autophagy, integrins and syndecans pathways in C6 glial cells.


Subject(s)
Astrocytes/pathology , Autophagy/drug effects , Parkinson Disease, Secondary/genetics , Parkinson Disease/metabolism , 1-Methyl-4-phenylpyridinium/toxicity , Animals , Apoptosis/drug effects , Astrocytes/drug effects , Autophagy/genetics , Cell Line , Disease Models, Animal , Humans , Insulin/pharmacology , Integrin alphaV/genetics , Integrin beta3/genetics , Nitric Oxide/metabolism , Parkinson Disease/genetics , Parkinson Disease/pathology , Parkinson Disease, Secondary/chemically induced , Parkinson Disease, Secondary/pathology , Phosphorylation , Rats , Signal Transduction/drug effects , Syndecan-1/genetics , Syndecan-3/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...